1998
HIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore
Zhang H, Flynn C, Nelson K, Chen W, Kawalski R, Vlahov D. HIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 397-398. PMID: 9704951, DOI: 10.1097/00042560-199808010-00018.Peer-Reviewed Original Research
1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1991
Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.
Viscidi R, Hill P, Li S, Cerny E, Vlahov D, Farzadegan H, Halsey N, Kelen G, Quinn T. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 1190-8. PMID: 1941526.Peer-Reviewed Original ResearchConceptsEnzyme immunoassayHTLV-IIAntibody reactivityPeptide enzyme immunoassayHTLV-II infectionEpidemiology of HTLVDifferentiation of HTLVMicrotiter plate enzyme immunoassaysPattern of reactivitySeronegative controlsEmergency departmentEnv peptidesPositive seraViral infectionNeurological diseasesHTLVSynthetic peptidesInfectionDrug abuseMajor envelope proteinEnvEnvelope proteinPatientsSerumAntibodies
1990
Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons
Vlahov D, Lee H, Taylor E, Canavaggio M, Canner C, Burczak J, Saah A. Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 531-535. DOI: 10.1097/00126334-199003050-00010.Peer-Reviewed Original ResearchHuman T-Lymphotropic Virus Type I/IIExact testIncoming male inmatesHIV-1 serostatusIntravenous drug usersPrevalence of HTLVFisher's exact testYears of ageSame calendar periodWestern blot techniqueType I/IIEpidemiological serosurveyMale inmatesScope of infectionRisk groupsCalendar periodHIV-1Drug usersHTLVMaryland prisonsBlot techniqueRoutine operational proceduresAntibodiesYear of entrySerostatusAntibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons
Vlahov D, Lee H, Taylor E, Canavaggio M, Canner C, Burczak J, Saah A. Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 531-535. PMID: 1969961, DOI: 10.1097/00126334-199005000-00010.Peer-Reviewed Original ResearchConceptsHuman T-Lymphotropic Virus Type I/IIExact testIncoming male inmatesHIV-1 serostatusIntravenous drug usersPrevalence of HTLVFisher's exact testYears of ageSame calendar periodWestern blot techniqueType I/IIEpidemiological serosurveyScope of infectionMale inmatesCalendar periodRisk groupsHIV-1Drug usersHTLVMaryland prisonsChi 2Blot techniqueRoutine operational proceduresAntibodiesYear of entry